Toxic amyloid-beta (Aβ) plaque and harmful inflammation are two leading symptoms of Alzheimer's disease (AD). This research designs a near-infrared-II aggregation-induced emission (AIE) nanotheranostic for precise AD therapy. The nanotheranostic's in vivo BBB penetration and specific plaque binding are monitored, and ROS triggers the release of two AIE molecules to inhibit Aβ fibril formation, degrade Aβ fibrils, prevent reaggregation, scavenge ROS, and alleviate inflammation. This leads to behavioral and cognitive improvements in a female AD mouse model.
